NS Partners Ltd reduced its stake in Stryker Corporation (NYSE:SYK – Free Report) by 22.3% during the 2nd quarter, HoldingsChannel reports. The firm owned 83,396 shares of the medical technology company’s stock after selling 23,868 shares during the quarter. NS Partners Ltd’s holdings in Stryker were worth $26,256,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the stock. Gables Capital Management Inc. bought a new stake in shares of Stryker in the 2nd quarter worth about $25,000. Kilter Group LLC acquired a new stake in shares of Stryker during the second quarter worth approximately $25,000. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker during the fourth quarter worth approximately $26,000. Sankala Group LLC bought a new position in shares of Stryker in the fourth quarter valued at approximately $26,000. Finally, Compass Financial Management LLC acquired a new position in shares of Stryker in the 2nd quarter worth approximately $27,000. 77.09% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the company. UBS Group initiated coverage on Stryker in a research report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price objective for the company. Raymond James Financial set a $370.00 target price on shares of Stryker in a research note on Friday, July 31st. Evercore set a $350.00 price target on shares of Stryker in a research note on Monday, July 6th. BMO Capital Markets initiated coverage on shares of Stryker in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective for the company. Finally, Citizens Jmp lowered their target price on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.
Insider Buying and Selling
In other Stryker news, insider Debra King sold 826 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda E. Stryker sold 300,000 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares in the company, valued at $773,031,862.50. This trade represents a 11.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 351,267 shares of company stock valued at $118,197,701. Company insiders own 4.60% of the company’s stock.
Stryker Price Performance
SYK opened at $324.32 on Tuesday. The company has a fifty day moving average price of $329.49 and a two-hundred day moving average price of $331.03. The firm has a market capitalization of $124.40 billion, a PE ratio of 33.61, a P/E/G ratio of 2.11 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86.
Stryker (NYSE:SYK – Get Free Report) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the firm earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.
Stryker Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.
Stryker Company Profile
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Featured Stories
- Five stocks we like better than Stryker
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
